Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Optimal Management Of Immune-related Toxicities Associated With Checkpoint Inhibitors In Lung Cancer.

M. Howell, R. Lee, S. Bowyer, A. Fusi, P. Lorigan
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Antibodies against immune checkpoints including CTLA-4, PD-1 and PD-L1 are increasingly being used in lung cancer. They are associated with novel, immune related toxicities not previously encountered with established treatments for lung cancer including colitis, hepatitis, rashes, neuropathies and other rarer immune mediated toxicities. Although generally these are low grade, there is a potential to be life threatening if not managed promptly. Early recognition of toxicity and institution of management algorithms are key to ensuring patient safety. We review the common toxicities and provide recommendations on their management.
This paper references
10.1097/CJI.0b013e31827807dd
A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.
C. Gaudy-Marqueste (2013)
10.1056/NEJMoa1305133
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
10.1200/JCO.2014.32.15_SUPPL.8007
Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).
N. Rizvi (2014)
10.1007/s11060-014-1400-y
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
P. Queirolo (2014)
10.1200/JCO.2014.32.15_SUPPL.8112
Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.
J. Brahmer (2014)
10.1016/S0140-6736(08)61758-4
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
E. Kim (2008)
10.1200/jco.2014.32.18_suppl.lba9000
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
F. S. Hodi (2014)
10.1200/JCO.2013.31.15_SUPPL.8072
A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).
N. Rizvi (2013)
10.1056/NEJMc0904283
Anti-CTLA4 antibody-induced lupus nephritis.
F. Fadel (2009)
10.1093/ANNONC/MDU438.51
LBA43ANTITUMOR ACTIVITY OF PEMBROLIZUMAB (PEMBRO; MK-3475) AND CORRELATION WITH PROGRAMMED DEATH LIGAND 1 (PD-L1) EXPRESSION IN A POOLED ANALYSIS OF PATIENTS (PTS) WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA (NSCLC)
E. Garon (2014)
10.1200/jco.2014.32.18_suppl.lba9008
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.
V. Chiarion-Sileni (2014)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1200/JCO.2011.38.4032
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
T. Lynch (2012)
10.1056/NEJMoa1214886
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
A. Shaw (2013)
10.1093/ANNONC/MDW326
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
S. Novello (2016)
10.1093/annonc/mdq207
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
L. Crinò (2010)
10.1056/NEJMoa1412082
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
10.1371/journal.pone.0053745
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J Voskens (2013)
10.1200/EdBook_AM.2013.33.e280
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
L. Chow (2013)
10.1038/clpt.2014.74
Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
R. Harvey (2014)
10.1200/JCO.2010.32.2206
Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.
Katarzyna Chmiel (2011)
10.1200/JCO.2014.32.15_SUPPL.9024
Clustered genomic variants specific to patients who develop immune-related colitis after ipilimumab for prediction of toxicity.
A. Tarhini (2014)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.2214/AJR.10.6198
Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
Y. Bronstein (2011)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
10.1053/j.seminoncol.2010.09.007
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
A. M. Di Giacomo (2010)
10.1200/JCO.2013.53.0105
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
Anti - CTLA 4 antibody - induced lupus nephri
F Fadel (2009)
10.1089/cbr.2008.0607
Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
D. Minor (2009)
10.1200/JCO.2012.41.6750
Management of immune-related adverse events and kinetics of response with ipilimumab.
J. Weber (2012)
10.1158/1078-0432.CCR-09-1024
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
10.1093/ANNONC/MDU438.34
LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY
J. Weber (2014)
10.1016/S0140-6736(14)60958-2
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C. Robert (2014)
10.1016/S1470-2045(11)70393-X
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
R. Rosell (2012)
10.1056/NEJMoa1302369
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
10.1038/nrclinonc.2013.245
Mitigating the toxic effects of anticancer immunotherapy
Tara C. Gangadhar (2014)
10.1097/CJI.0b013e318193a206
Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
S. Bhatia (2009)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
10.1093/annonc/mdt178
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
M. Frueh (2013)
10.1200/JCO.2011.29.15_SUPPL.8583
Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
R. Ibrahim (2011)
10.1200/JCO.2013.51.1683
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.
D. Johnson (2015)
10.1634/theoncologist.13-S4-2
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
J. Wolchok (2008)
10.1093/annonc/mdq172
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
M. Sørensen (2010)
10.1093/annonc/mdr028
Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
S. Wilgenhof (2011)
10.1200/JCO.2010.28.15_SUPPL.8571
Hair depigmentation as an indicator of durable response to CTLA-4 therapy.
A. Pavlick (2010)
10.1200/JCO.2005.06.205
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
10.1200/jco.2014.32.18_suppl.lba9003
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
H. Kluger (2014)
10.1158/1078-0432.CCR-07-0187
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
10.1186/1479-5876-12-116
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
P. Ascierto (2014)
10.1200/JCO.2010.28.18_SUPPL.4
A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.
S. O'Day (2010)



This paper is referenced by
10.1177/1758835918764628
Clinical assessment of immune-related adverse events
A. Sosa (2018)
10.3949/ccjm.85a.18020
How should we diagnose and manage checkpoint inhibitor-associated colitis?
F. Khan (2018)
Nivolumab — perspectives in cancer treatment
H. Koseła (2016)
10.1002/ccr3.2122
Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non–small‐cell lung cancer
D. Kim (2019)
10.1055/S-0043-103471
Individualisierte Therapie des metastasierten Lungenkarzinoms
Georg Evers (2017)
10.1016/j.clinimag.2020.02.006
Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist.
V. Furtado (2020)
10.21037/ATM.2019.05.58
Immunotherapy and targeted therapy-the new roadmap in cancer treatment.
Kamran Shahid (2019)
10.1183/13993003.01721-2016
Comorbidities in the management of patients with lung cancer
C. Leduc (2017)
10.1164/rccm.201906-1202ST
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement
C. Sears (2019)
10.1158/0008-5472.CAN-16-2324
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
D. Oh (2017)
10.3892/or.2016.4589
Induction of eEF2-specific antitumor CTL responses in vivo by vaccination with eEF2-derived 9mer-peptides.
H. Nakajima (2016)
10.2147/DDDT.S148443
The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer
Wenjie Guo (2017)
10.3390/cancers11030305
Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
M. Porcu (2019)
10.1007/s10269-015-2544-x
Checkpoint immunologique comme cible thérapeutique
S. Champiat (2015)
10.1038/nrclinonc.2017.60
Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?
P. Lorigan (2017)
10.2147/OTT.S111209
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment
H. El-Osta (2016)
10.1136/esmoopen-2016-000145
Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
R. Kato (2017)
10.2217/imt-2016-0029
Immune checkpoint inhibitors side effects and management.
H. Kourie (2016)
10.1111/imm.13141
Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Petros Fessas (2019)
10.1007/978-3-030-41008-7_12
Gastrointestinal Tract Adverse Events.
Hamzah Abu-Sbeih (2020)
10.4103/apjon.apjon_4_17
Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
Jennifer Dine (2017)
10.1097/CMR.0000000000000256
Safety of immune checkpoint inhibitors in Chinese patients with melanoma
X. Wen (2016)
10.1186/s40425-015-0078-9
Pembrolizumab
L. Khoja (2015)
10.1016/j.cpccr.2020.100014
Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer
S. Andrews (2020)
Advances in immunotherapy for non-small cell lung cancer.
K. Reckamp (2015)
10.3779/j.issn.1009-3419.2020.02.01
[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)].
C. Zhou (2020)
10.1016/j.intimp.2020.106601
Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Yingying Hu (2020)
10.1021/acsnano.7b01786
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.
Lei Miao (2017)
10.1097/CCO.0000000000000305
Checkpoint inhibitors: outstanding efficacy but at what cost?
J. Klastersky (2016)
10.1007/978-3-030-02505-2_7
Immune Checkpoint Inhibitors-Induced Colitis.
Y. Tian (2018)
10.1053/j.seminoncol.2015.09.017
Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.
M. Socinski (2015)
10.5772/66841
Checkpoint Inhibitors in Nonsmall Cell Lung Cancer
Karen Zeman (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar